3 ms·
90% reduction of progression to Type 2 diabetes vs placebo in a phase 3, double-blind, randomized, controlled trial with >2,500 participants with obesity.
by nabla9 2y ago
90% reduction of progression to Type 2 diabetes vs placebo in a phase 3, double-blind, randomized, controlled trial with >2,500 participants with obesity.